| Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock |
ATLANTA , May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025 (the "Existing Convertible Notes"). Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for a number of shares of the company's common stock to be determined based on the trading price of the common stock over a four trading day averaging period beginning on May 15, 2025 (the "Shares"). |
prnewswire.com |
2025-05-14 20:01:00 |
Czytaj oryginał (ang.) |
| Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript |
Artivion, Inc. (NYSE:AORT ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants John McAulay - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion's First Quarter 2025 Financial Conference Call. |
seekingalpha.com |
2025-05-06 02:37:09 |
Czytaj oryginał (ang.) |
| Artivion (AORT) Lags Q1 Earnings Estimates |
Artivion (AORT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.06 per share a year ago. |
zacks.com |
2025-05-05 22:51:20 |
Czytaj oryginał (ang.) |
| Artivion Reports First Quarter 2025 Financial Results |
First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basis Net loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025 Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 2024 30-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference performance goal Submitted the clinical module of the pre-market approval application (PMA) to the FDA for the AMDS Hybrid Prosthesis ATLANTA , May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2025. "I am pleased with our first quarter results as we returned to normal operations following our previously disclosed cybersecurity incident while making substantial progress on our strategic growth initiatives. |
prnewswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting |
30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA , May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS. |
prnewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results |
ATLANTA , April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. |
prnewswire.com |
2025-04-21 20:10:00 |
Czytaj oryginał (ang.) |
| Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength? |
Artivion (AORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-04-10 14:11:19 |
Czytaj oryginał (ang.) |
| Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference |
ATLANTA , March 4, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. |
prnewswire.com |
2025-03-04 18:05:00 |
Czytaj oryginał (ang.) |
| Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround |
Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-02-27 12:35:40 |
Czytaj oryginał (ang.) |
| Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript |
Artivion, Inc. (NYSE:AORT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Fourth Quarter and Year End 2024 Financial Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. |
seekingalpha.com |
2025-02-25 01:00:16 |
Czytaj oryginał (ang.) |
| Artivion (AORT) Reports Break-Even Earnings for Q4 |
Artivion (AORT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.12. This compares to earnings of $0.11 per share a year ago. |
zacks.com |
2025-02-24 20:21:34 |
Czytaj oryginał (ang.) |
| Artivion Reports Fourth Quarter and Full Year 2024 Financial Results |
Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basis Achieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal year Adjusted EBITDA increased 15% to $17.6 million in the fourth quarter of 2024 compared to $15.3 million in the fourth quarter of 2023. |
prnewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results |
ATLANTA , Feb. 10, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 financial results will be released on Monday, February 24, 2025 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. |
prnewswire.com |
2025-02-10 18:10:00 |
Czytaj oryginał (ang.) |
| On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks. |
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth. |
investors.com |
2025-02-03 17:09:34 |
Czytaj oryginał (ang.) |
| Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting |
Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA , Jan. 27, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking Science presentation at the 61st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation. |
prnewswire.com |
2025-01-27 10:00:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for January 7th |
NN, VERX and AORT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 7, 2024. |
zacks.com |
2025-01-07 13:25:40 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 7th |
AORT, VERX, NN, IMCR and EVER have been added to the Zacks Rank #1 (Strong Buy) List on January 7, 2024. |
zacks.com |
2025-01-07 10:21:11 |
Czytaj oryginał (ang.) |
| US medical device giant Artivion says hackers stole files during cybersecurity incident |
Artivion, a medical device company that manufactures implantable tissues for cardiac and vascular transplant applications, says its services have been “disrupted” due to a cybersecurity incident. |
techcrunch.com |
2024-12-09 12:52:32 |
Czytaj oryginał (ang.) |
| Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis |
ATLANTA , Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis ("AMDS") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections. |
prnewswire.com |
2024-12-09 10:00:00 |
Czytaj oryginał (ang.) |
| Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript |
Artivion, Inc. (NYSE:AORT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Daniel Stauder - JMP Securities Suraj Kalia - Oppenheimer Nelson Cox - Lake Street Capital Mike Matson - Needham & Company Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Third Quarter 2024 Financial Conference Call. At this time, all participants are in listen only mode. |
seekingalpha.com |
2024-11-09 14:02:09 |
Czytaj oryginał (ang.) |
| Artivion (AORT) Tops Q3 Earnings and Revenue Estimates |
Artivion (AORT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago. |
zacks.com |
2024-11-07 21:10:54 |
Czytaj oryginał (ang.) |
| Artivion Reports Third Quarter 2024 Financial Results |
Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis Net loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024 Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023 Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug Administration Enrollment completed in NEXUS TRIOMPHE clinical trial Received regulatory approval from the National Medical Products Administration (NMPA) to commercialize BioGlue Surgical Adhesive in China. Commercialization expected in the second half of 2025. |
prnewswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| Artivion to Participate in Upcoming Investor Conferences |
ATLANTA , Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at the Lotte New York Palace. |
prnewswire.com |
2024-11-05 18:15:00 |
Czytaj oryginał (ang.) |
| Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results |
ATLANTA , Oct. 24, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial results will be released on Thursday, November 7, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. |
prnewswire.com |
2024-10-24 20:15:00 |
Czytaj oryginał (ang.) |
| Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting |
5-Year Data from the AMDS DARTS Trial Demonstrates Positive Aortic Remodeling with 94% of Patients Free from Unanticipated Reoperation 30-Day Data from the AMDS PERSEVERE Trial Shows Cerebral Malperfusion Resolution in 90% of Affected Subjects Post-AMDS Implantation 1-Year Data from the NEOS Study Indicate E-vita Open Neo is Safe and Effective in the Treatment of Aortic Arch Pathologies with Low Combined Major Adverse Events Rate ATLANTA , Oct. 10, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS DARTS and PERSEVERE trials and E-vita Open Neo study presented in Late-Breaking Science presentations at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon, Portugal. The presentation regarding the AMDS DARTS trial highlighted 5-year aortic remodeling data that demonstrate positive, durable patient outcomes following AMDS implantation. |
prnewswire.com |
2024-10-10 20:10:00 |
Czytaj oryginał (ang.) |
| Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript |
Artivion, Inc. (NYSE:AORT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Suraj Kalia - Oppenheimer John McAulay - Stifel Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. And welcome to Artivion's Second Quarter 2024 Financial Conference Call. |
seekingalpha.com |
2024-08-10 18:45:26 |
Czytaj oryginał (ang.) |
| Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates |
Artivion (AORT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.06 per share a year ago. |
zacks.com |
2024-08-08 22:50:51 |
Czytaj oryginał (ang.) |
| Artivion Reports Second Quarter 2024 Financial Results |
Second Quarter Highlights: Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency basis Net loss was ($2.1) million or ($0.05) per fully diluted share and non-GAAP net income was $2.9 million or $0.07 per fully diluted share in the second quarter of 2024 Adjusted EBITDA increased 35% to $18.6 million in the second quarter of 2024 compared to $13.8 million in the second quarter of 2023 Raised FY24 revenue guidance to 10% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint Raised FY24 adjusted EBITDA guidance to 28% to 34% year-over-year growth, an increase of 1% at the midpoint ATLANTA , Aug. 8, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2024. "In the second quarter, we continued to make substantial progress on our strategic growth initiatives to drive sustained and profitable growth, and we further solidified our position as the leader in the aortic disease space. |
prnewswire.com |
2024-08-08 20:05:00 |
Czytaj oryginał (ang.) |
| Artivion to Participate in Upcoming Investor Conferences |
ATLANTA , Aug. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at the InterContinental Boston Hotel. |
prnewswire.com |
2024-08-05 20:10:00 |
Czytaj oryginał (ang.) |
| Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results |
ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. |
prnewswire.com |
2024-07-25 20:10:00 |
Czytaj oryginał (ang.) |
| 3 Earnings All-Stars With More Room to Run |
Earnings are essential to determining which stocks will outperform. Unsurprisingly, earnings outperformers also see strong price appreciation. |
investorplace.com |
2024-07-03 12:00:00 |
Czytaj oryginał (ang.) |
| Artivion Amends Agreements with Endospan |
Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $100 million earnout minimum eliminated ATLANTA , July 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer of the NEXUS® Stent Graft System ("NEXUS"). |
prnewswire.com |
2024-07-01 20:05:00 |
Czytaj oryginał (ang.) |
| Data-Driven Growth Fuels More Upside For Overlooked Artivion |
Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval trial data for the On-X aortic valve and a successful PERSEVERE IDE study for AMDS hybrid prosthesis can drive additional revenue growth. A strong pipeline, including NEXUS and ARCEVO stent graft systems, can support a longer runway of continued revenue growth. |
seekingalpha.com |
2024-06-21 21:01:54 |
Czytaj oryginał (ang.) |
| Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue? |
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-05-08 14:17:14 |
Czytaj oryginał (ang.) |
| Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript |
Artivion, Inc. (NYSE:AORT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Suraj Kalia - Oppenheimer & Company Frank Takkinen - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion First Quarter 2024 Financial Conference Call. |
seekingalpha.com |
2024-05-07 02:47:07 |
Czytaj oryginał (ang.) |
| Artivion (AORT) Tops Q1 Earnings and Revenue Estimates |
Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago. |
zacks.com |
2024-05-06 22:21:04 |
Czytaj oryginał (ang.) |
| Artivion Reports First Quarter 2024 Financial Results |
First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $7.5 million or $0.18 per fully diluted share and non-GAAP net income was $2.6 million or $0.06 per fully diluted share in the first quarter of 2024 Non-GAAP adjusted EBITDA increased 60% to $17.3 million in the first quarter of 2024 compared to $10.8 million in the first quarter of 2023 Revised FY24 revenue guidance to 9% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint ATLANTA , May 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2024. "We are very pleased with our first quarter results as we maintained growth momentum and executed on key operational priorities. |
prnewswire.com |
2024-05-06 20:05:00 |
Czytaj oryginał (ang.) |